On the recordJuly 20, 2010
One challenge that many of the witnesses today spoke of is the need to incentivize the device and drug/biotech industry to develop therapeutics for rare, pediatric diseases.
Source
congress.govOne challenge that many of the witnesses today spoke of is the need to incentivize the device and drug/biotech industry to develop therapeutics for rare, pediatric diseases.
Hagan emphasizes the need for incentives in developing treatments for rare pediatric diseases.
Share
More from Kay Hagan
Do you see the presence of radicalized Westerners fighting with ISIS and the Khorasan as a threat to the United States?
What can be done to improve the evidence gathering, the data collection, so that the Federal, State, and local policymakers can better address this problem?
I also think it's critical that the people of Syria have an alternative other than ISIS or other radical terrorist groups like it or the Assad regime.